Premium Reports
Contact KLAS
 Download Report    Zoom in charts

Preferences

   Bookmark

Related Series

 No Related Series

 End chart zoom
Ibex Medical Analytics 2023 Ibex Medical Analytics 2023
* A page refresh may be necessary to see the updated image

Ibex Medical Analytics 2023
Providing Increased Accuracy and Efficiency in Digital Pathology for Primary Diagnosis

author - Eder Lagemann
Author
Eder Lagemann
author - Steve VanWagenen
Author
Steve VanWagenen
author - Joshua Urry
Author
Joshua Urry
 
June 30, 2023 | Read Time: 1  minute

As digital pathology for primary diagnosis expands across the world, artificial intelligence (AI) promises to drive key benefits from digital transformation—the primary benefits being increased diagnostic accuracy and pathologist efficiency. Ibex Medical Analytics’ Galen suite of AI solutions provides algorithms to assist pathologists with the identification and grading of cancer regions as well as provides various other decision support tools in digital pathology. This report validates customers’ experiences with this program.

to see the full dataset.

If you don't have a login, getting started is easy.

Provider Organizations
Fill out our registration form to verify your organization.
HIT Companies
Contact a KLAS representative for plans and pricing.

Key Findings:

  1. Ibex Medical Analytics Customer Experience: An Initial Look
  2. Points to Ponder
  3. Ibex Medical Analytics: Company Profile at a Glance
  4. Solution Technical Specifications (provided by Ibex Medical Analytics)
author - Robert Ellis
Project Manager
Robert Ellis
 Download Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2024 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.